ClinicalTrials.gg
CompletedNCT02242045Updated Mar 19, 2021Results posted

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

A Phase 1 interventional study of Idelalisib in Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Gilead Sciences. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
23rd of 25
6 · median 102
Started
2014
with 3 others
Phase 1
3 of 25
none open now
Registered
18th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 23rd largest by enrollment, is one of 4 that started in 2014, is one of 3 in phase 1, and was the 18th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Indolent Non-Hodgkin Lymphoma
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)
  • Marginal Zone Lymphoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with mature B-cell of iNHL including follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, and CLL by World Health Organization classification
  • Must have been born in Japan and must not have lived outside of Japan for > 1 year in the 5 years prior to Day 1
  • Must be able to trace maternal and paternal ancestry of parents and grandparents as Japanese
  • Must have been previously treated with at least 1 regimen for iNHL or CLL and currently require treatment
  • Discontinuation of all therapy (including radiotherapy, chemotherapy, immunotherapy, or therapy) for the treatment of iNHL or CLL ≥ 4 weeks prior to Day 1
  • performance status of 0 or 1
  • Required baseline laboratory data (within 4 weeks prior to Day 1)
  • A negative serum pregnancy test for female participants of
  • Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of .
  • In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the individual's disease.

Key Exclusion Criteria:

  • Known histological transformation to an aggressive histology
  • Known presence of myelodysplastic syndrome
  • History of iNHL or CLL with central nervous system involvement
  • \< 120 days as per investigator assessment
  • History of a nonlymphoid malignancy with the following exceptions:

    • the malignancy has been in remission without treatment for ≥ 5 years prior to Day 1, or
    • carcinoma in situ of the cervix, or
    • adequately treated basal or squamous cell skin cancer or other localized nonmelanoma skin cancer, or
    • surgically treated low-grade prostate cancer, or
    • ductal carcinoma in situ of the breast treated with lumpectomy alone
  • On-going drug-induced liver injury, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
  • History or diagnosis of pneumonitis or interstitial lung disease.
  • On-going inflammatory bowel disease
  • Pregnancy or breastfeeding
  • History of prior allogeneic hematopoietic stem cell or solid organ transplantation
  • Concurrent participation in another therapeutic clinical trial
  • Prior or on-going illness, medical condition, surgical history, physical finding, finding, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the individual or impair the assessment of study results.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.

    Drug: Idelalisib

Interventions

  • 150 mg tablet(s) administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 28 days

  2. Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 28 days

  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent.The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.

    Time frame: First dose date up to 28 days

  4. Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 28 days

  5. Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 1

    Lower limit of quantitation was 5 ng/mL for idelalisib and metabolite GS-563117 both.

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 1

  6. Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 8

    Time frame: Predose and 1.5 hours postdose on Day 8

  7. Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 15

    Time frame: Predose and 1.5 hours postdose on Day 15

  8. Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 22

    Time frame: Predose and 1.5 hours postdose on Day 22

  9. Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 29

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 29

Secondary outcomes

  1. Percentage of Participants Experiencing TEAEs and SAEs Beyond 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)

  2. Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)

  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per CTCAE, Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.

    Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)

  4. Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure

    An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)

07

Results

Posted Mar 19, 2021

Participant flow

Participants were enrolled at study sites in Japan. The first participant was screened on 01 October 2014. The last study visit occurred on 17 October 2017.

Participant flow — Overall Study
MilestoneIdelalisib
Started6
Completed0
Not completed6
Withdrew: Investigator's discretion1
Withdrew: Progressive disease2
Withdrew: Unable to tolerate rechallenge with idelalisib1
Withdrew: Initiated another anti-cancer or experimental therapy2

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 28 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
TEAEs66.7
SAEs16.7
PrimaryPercentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 28 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure0
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent.The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.

Time frame:
First dose date up to 28 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
percentage of participantsIdelalisib
Leukocytosis (Grade 1)0
Leukocytosis (Grade 2)0
Leukocytosis (Grade 3)16.7
Leukocytosis (Grade 4)0
White blood cell decreased (Grade 1)16.7
White blood cell decreased (Grade 2)0
White blood cell decreased (Grade 3)16.7
White blood cell decreased (Grade 4)0
Neutrophil count decreased (Grade 1)16.7
Neutrophil count decreased (Grade 2)16.7
Neutrophil count decreased (Grade 3)0
Neutrophil count decreased (Grade 4)0
Hypocalcemia (Grade 1)0
Hypocalcemia (Grade 2)16.7
Hypocalcemia (Grade 3)0
Hypocalcemia (Grade 4)0
Cholesterol high (Grade 1)33.3
Cholesterol high (Grade 2)0
Cholesterol high (Grade 3)0
Cholesterol high (Grade 4)0
Creatinine increased (Grade 1)16.7
Creatinine increased (Grade 2)0
Creatinine increased (Grade 3)0
Creatinine increased (Grade 4)0
Chronic Kidney Disease (Grade 1)0
Chronic Kidney Disease (Grade 2)33.3
Chronic Kidney Disease (Grade 3)0
Chronic Kidney Disease (Grade 4)0
Hypertriglyceridemia (Grade 1)33.3
Hypertriglyceridemia (Grade 2)16.7
Hypertriglyceridemia (Grade 3)0
Hypertriglyceridemia (Grade 4)0
PrimaryPercentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 28 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure0
PrimaryPlasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 1

Lower limit of quantitation was 5 ng/mL for idelalisib and metabolite GS-563117 both.

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 1
Reported as:
Mean · ng/mL
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 1
ng/mLIdelalisib
Idelalisib: PredoseNA ± NA
Idelalisib: 0.5 hour188.4 ± 322.97
Idelalisib: 1 hour763.9 ± 1141.85
Idelalisib: 1.5 hour1454.0 ± 1255.23
Idelalisib: 2 hour2097.4 ± 1483.25
Idelalisib: 3 hour2226.5 ± 1231.66
Idelalisib: 4 hour2042.3 ± 1048.57
Idelalisib: 6 hour1215.0 ± 797.50
Idelalisib: 8 hour718.5 ± 532.06
Idelalisib: 12 hour291.4 ± 247.66
GS-563117: PredoseNA ± NA
GS-563117: 0.5 hour6.38 ± 7.095
GS-563117: 1 hour134.92 ± 153.644
GS-563117: 1.5 hour478.75 ± 507.114
GS-563117: 2 hour1005.12 ± 781.188
GS-563117: 3 hour2011.00 ± 1206.687
GS-563117: 4 hour2121.00 ± 1352.570
GS-563117: 6 hour2288.33 ± 1358.446
GS-563117: 8 hour2195.00 ± 1494.054
GS-563117: 12 hour1677.83 ± 1307.384
PrimaryPlasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 8
Time frame:
Predose and 1.5 hours postdose on Day 8
Reported as:
Mean · ng/mL
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 8
ng/mLIdelalisib
Idelalisib: Predose463.2 ± 220.75
Idelalisib: 1.5 hour2138.5 ± 759.23
GS-563117: Predose2703.33 ± 1866.555
GS-563117: 1.5 hour3040.00 ± 1736.237
PrimaryPlasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 15
Time frame:
Predose and 1.5 hours postdose on Day 15
Reported as:
Mean · ng/mL
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 15
ng/mLIdelalisib
Idelalisib: Predose459.3 ± 203.64
Idelalisib: 1.5 hour2648.3 ± 1601.70
GS-563117: Predose3326.67 ± 2655.234
GS-563117: 1.5 hour3636.67 ± 2547.883
PrimaryPlasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 22
Time frame:
Predose and 1.5 hours postdose on Day 22
Reported as:
Mean · ng/mL
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 22
ng/mLIdelalisib
Idelalisib: Predose358.7 ± 237.86
Idelalisib: 1.5 hour2155.0 ± 782.73
GS-563117: Predose2318.33 ± 1070.111
GS-563117: 1.5 hour2828.33 ± 1749.153
PrimaryPlasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 29
Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 29
Reported as:
Mean · ng/mL
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 29
ng/mLIdelalisib
Idelalisib: Predose501.2 ± 329.02
Idelalisib: 0.5 hour666.8 ± 454.58
Idelalisib: 1 hour1107.8 ± 891.69
Idelalisib: 1.5 hour1523.3 ± 990.84
Idelalisib: 2 hour1940.0 ± 1028.47
Idelalisib: 3 hour2313.3 ± 644.13
Idelalisib: 4 hour1843.8 ± 701.36
Idelalisib: 6 hour1141.2 ± 509.70
Idelalisib: 8 hour707.2 ± 340.26
Idelalisib: 12 hour403.0 ± 315.41
GS-563117: Predose Day 293075.00 ± 2546.698
GS-563117: 0.5 hour2913.33 ± 2855.182
GS-563117: 1 hour2833.33 ± 2535.387
GS-563117: 1.5 hour2930.00 ± 2585.660
GS-563117: 2 hour3185.00 ± 2799.691
GS-563117: 3 hour3781.67 ± 3058.283
GS-563117: 4 hour3893.33 ± 2996.309
GS-563117: 6 hour3653.33 ± 2900.232
GS-563117: 8 hour3428.33 ± 2987.376
GS-563117: 12 hour2871.67 ± 3309.601
SecondaryPercentage of Participants Experiencing TEAEs and SAEs Beyond 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 30 days after last dose (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing TEAEs and SAEs Beyond 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
TEAEs100.0
SAEs83.3
SecondaryPercentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 30 days after last dose (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure83.3
SecondaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per CTCAE, Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.

Time frame:
First dose date up to 30 days after last dose (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
percentage of participantsIdelalisib
Anemia (Grade 1)0
Anemia (Grade 2)16.7
Anemia (Grade 3)0
Anemia (Grade 4)0
Leukocytosis (Grade 1)0
Leukocytosis (Grade 2)0
Leukocytosis (Grade 3)16.7
Leukocytosis (Grade 4)0
White blood cell decreased (Grade 1)50.0
White blood cell decreased (Grade 2)0
White blood cell decreased (Grade 3)16.7
White blood cell decreased (Grade 4)0
Lymphocyte count decreased (Grade 1)0
Lymphocyte count decreased (Grade 2)16.7
Lymphocyte count decreased (Grade 3)16.7
Lymphocyte count decreased (Grade 4)0
Neutrophil count decreased (Grade 1)33.3
Neutrophil count decreased (Grade 2)16.7
Neutrophil count decreased (Grade 3)33.3
Neutrophil count decreased (Grade 4)0
Alanine aminotransferase increased (Grade 1)33.3
Alanine aminotransferase increased (Grade 2)0
Alanine aminotransferase increased (Grade 3)0
Alanine aminotransferase increased (Grade 4)16.7
Hypoalbuminemia (Grade 1)0
Hypoalbuminemia (Grade 2)16.7
Hypoalbuminemia (Grade 3)0
Hypoalbuminemia (Grade 4)0
Hypocalcemia (Grade 1)0
Hypocalcemia (Grade 2)16.7
Hypocalcemia (Grade 3)0
Hypocalcemia (Grade 4)0
Alkaline phosphatase increased (Grade 1)16.7
Alkaline phosphatase increased (Grade 2)0
Alkaline phosphatase increased (Grade 3)0
Alkaline phosphatase increased (Grade 4)0
Aspartate aminotransferase increased (Grade 1)33.3
Aspartate aminotransferase increased (Grade 2)0
Aspartate aminotransferase increased (Grade 3)16.7
Aspartate aminotransferase increased (Grade 4)0
Blood bilirubin increased (Grade 1)16.7
Blood bilirubin increased (Grade 2)0
Blood bilirubin increased (Grade 3)0
Blood bilirubin increased (Grade 4)0
Cholesterol high (Grade 1)16.7
Cholesterol high (Grade 2)16.7
Cholesterol high (Grade 3)0
Cholesterol high (Grade 4)0
Creatinine increased (Grade 1)50.0
Creatinine increased (Grade 2)16.7
Creatinine increased (Grade 3)0
Creatinine increased (Grade 4)0
Chronic Kidney Disease (Grade 1)0
Chronic Kidney Disease (Grade 2)50.0
Chronic Kidney Disease (Grade 3)16.7
Chronic Kidney Disease (Grade 4)0
Gamma Glutamyl Transferase increased (Grade 1)50.0
Gamma Glutamyl Transferase increased (Grade 2)16.7
Gamma Glutamyl Transferase increased (Grade 3)0
Gamma Glutamyl Transferase increased (Grade 4)0
Hyperglycemia (Grade 1)50.0
Hyperglycemia (Grade 2)0
Hyperglycemia (Grade 3)16.7
Hyperglycemia (Grade 4)0
Hypophosphatemia (Grade 1)0
Hypophosphatemia (Grade 2)16.7
Hypophosphatemia (Grade 3)33.3
Hypophosphatemia (Grade 4)0
Hypokalemia (Grade 1)0
Hypokalemia (Grade 2)0
Hypokalemia (Grade 3)16.7
Hypokalemia (Grade 4)16.7
Hyponatremia (Grade 1)33.3
Hyponatremia (Grade 2)0
Hyponatremia (Grade 3)0
Hyponatremia (Grade 4)0
Hypertriglyceridemia (Grade 1)33.3
Hypertriglyceridemia (Grade 2)0
Hypertriglyceridemia (Grade 3)33.3
Hypertriglyceridemia (Grade 4)0
Hyperuricemia (Grade 1)33.3
Hyperuricemia (Grade 2)0
Hyperuricemia (Grade 3)0
Hyperuricemia (Grade 4)0
SecondaryPercentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure

An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 30 days after last dose (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure
percentage of participantsIdelalisib
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure16.7

Adverse events

Collected over First dose date up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib0/6 (0%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventIdelalisib
DiarrhoeaGastrointestinal disorders3/6
PyrexiaGeneral disorders1/6
InfectionInfections and infestations1/6
PneumoniaInfections and infestations1/6
Transaminases increasedInvestigations1/6
Decreased appetiteMetabolism and nutrition disorders1/6
Most frequent other events
Showing 10 of 54
Most frequent other events
EventIdelalisib
DiarrhoeaGastrointestinal disorders5/6
GastritisGastrointestinal disorders3/6
PyrexiaGeneral disorders3/6
InsomniaPsychiatric disorders3/6
NauseaGastrointestinal disorders2/6
Herpes simplexInfections and infestations2/6
Upper respiratory tract infectionInfections and infestations2/6
Transaminases increasedInvestigations2/6
Weight decreasedInvestigations2/6
Decreased appetiteMetabolism and nutrition disorders2/6

Baseline characteristics

The Full Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Idelalisib
Mean62.3 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib
Female0
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Idelalisib
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Idelalisib
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Aichi, Japan
  • Miyagi, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Kinoshita T, Fukuhara N, Nagai H, Izutsu K, Kobayashi Y, et al. Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Abstract 85914]. Blood 2015;126:5089
  • Fukuhara N, Kinoshita T, Yamamoto K, Nagai H, Izutsu K, Yamamoto G, Bhargava P, Rajakumaraswamy N, Humeniuk R, Mathias A, Xing G, Fukui M, Tobinai K. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Jpn J Clin Oncol. 2020 Dec 16;50(12):1395-1402. doi: 10.1093/jjco/hyaa153. PubMed 32856068 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Dec 2014, 2 months.

Results were first posted in Mar 2021, 6 years 2 months after primary completion.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 2 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2014
First posted
Sep 16, 2014
StartActual
Oct 1, 2014
Primary completionActual
Dec 25, 2014
CompletionActual
Oct 17, 2017
Results first posted
Mar 19, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02242045
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 16, 2014
Start date
Oct 1, 2014
Primary completion
Dec 25, 2014
Completion
Oct 17, 2017
Results posted
Mar 19, 2021
Last update
Mar 19, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion